Cdc23 Inhibitors
Common Cdc23 Inhibitors include, but are not limited to Purvalanol A CAS 212844-53-6, Roscovitine CAS 186692-46-6, Flavopiridol CAS 146426-40-6, Indirubin-3'-monoxime CAS 160807-49-8 and RO-3306 CAS 872573-93-8.
Cdc23 inhibitors are a class of chemical compounds that specifically target and inhibit the activity of the Cdc23 protein, a crucial component of the anaphase-promoting complex/cyclosome (APC/C). The APC/C is a multi-subunit E3 ubiquitin ligase that plays a pivotal role in regulating the cell cycle by targeting specific proteins for degradation via the ubiquitin-proteasome pathway. Cdc23, along with other core subunits, is essential for the proper functioning of the APC/C, which in turn ensures the accurate progression of cells through mitosis and the maintenance of genomic stability. Inhibition of Cdc23 disrupts the activity of the APC/C, leading to the accumulation of key mitotic regulators and interference with the cell cycle progression, particularly in the metaphase-anaphase transition.
Chemically, Cdc23 inhibitors can vary widely in their structures but typically share a common feature of being able to bind to the Cdc23 protein or its interacting partners within the APC/C complex. This binding can occur through various mechanisms, such as direct interaction with the Cdc23 protein or by targeting the interfaces between Cdc23 and other APC/C components, thereby blocking the assembly or function of the complex. The specificity and potency of these inhibitors depend on their molecular configuration, which is often optimized through chemical modifications to enhance their binding affinity and stability. Understanding the structural basis of Cdc23 inhibition is crucial for designing more effective compounds that can selectively target this protein without affecting other cellular processes. Consequently, research into Cdc23 inhibitors focuses heavily on elucidating their binding mechanisms, structure-activity relationships, and the molecular dynamics involved in their interaction with the APC/C complex.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor that can interfere with the degradation of ubiquitinated proteins, potentially leading to an accumulation of proteins that are normally targeted for degradation. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG132 acts similarly to Bortezomib as a proteasome inhibitor, which can lead to an accumulation of proteins that are normally degraded by the proteasome. Cdc23, as a component of the APC/C, is involved in the ubiquitination of proteins for degradation. Thus, MG132 indirectly inhibits Cdc23 function by preventing the proteasomal degradation of its ubiquitination targets. | ||||||
Withaferin A | 5119-48-2 | sc-200381 sc-200381A sc-200381B sc-200381C | 1 mg 10 mg 100 mg 1 g | $127.00 $572.00 $4090.00 $20104.00 | 20 | |
Withaferin A is known to disrupt the proteasomal pathway by inhibiting the proteasome activity. Because Cdc23 functions in the APC/C, which tags proteins for degradation by the proteasome, Withaferin A can indirectly inhibit Cdc23 by hampering the degradation mechanism it relies upon. | ||||||
Celastrol, Celastrus scandens | 34157-83-0 | sc-202534 | 10 mg | $155.00 | 6 | |
Celastrol is an inhibitor of the proteasome, which can lead to disrupted degradation of proteins tagged by ubiquitination. Because Cdc23 is central to the function of the APC/C in ubiquitinating proteins for proteasomal degradation, Celastrol indirectly inhibits the function of Cdc23 by blocking the degradation pathway. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $134.00 $215.00 $440.00 $496.00 | 19 | |
Epoxomicin is a specific proteasome inhibitor that impedes the degradation of ubiquitinated proteins. Cdc23's role in the APC/C complex is to facilitate the ubiquitination of proteins for destruction. Therefore, Epoxomicin indirectly inhibits Cdc23 by stalling the proteasomal degradation process. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $165.00 $575.00 | 60 | |
Lactacystin is a proteasome inhibitor that prevents the degradation of proteins targeted by ubiquitination. Cdc23 is involved in the APC/C, which is crucial for ubiquitinating proteins for proteasomal degradation. Lactacystin's action can thus indirectly inhibit Cdc23 function by blocking the degradation path it targets. | ||||||
Carfilzomib | 868540-17-4 | sc-396755 | 5 mg | $40.00 | ||
Carfilzomib is a selective proteasome inhibitor that can obstruct the degradation of proteins destined for proteolysis. Cdc23, being part of the APC/C that ubiquitinates proteins for degradation, can be indirectly inhibited by Carfilzomib through disruption of the proteasomal degradation system. | ||||||
Oprozomib | 935888-69-0 | sc-477447 | 2.5 mg | $280.00 | ||
Oprozomib, another proteasome inhibitor, can lead to the accumulation of ubiquitinated proteins by blocking their degradation. Since Cdc23 is essential for the APC/C's role in tagging proteins for proteasomal degradation, Oprozomib can indirectly inhibit Cdc23 function by inhibiting the proteasome. | ||||||
Delanzomib, free base | 847499-27-8 | sc-396774 sc-396774A | 5 mg 10 mg | $160.00 $300.00 | ||
Delanzomib is a proteasome inhibitor that disrupts the degradation pathway of ubiquitinated proteins. By inhibiting the proteasome, Delanzomib indirectly inhibits Cdc23 by disrupting the proteasomal degradation process that is central to the function of the APC/C, of which Cdc23 is a part. | ||||||
Ixazomib | 1072833-77-2 | sc-489103 sc-489103A | 10 mg 50 mg | $311.00 $719.00 | ||
Ixazomib is a proteasome inhibitor that hinders the degradation of proteins targeted by the ubiquitination process. Since Cdc23 operates within the APC/C to promote ubiquitination for proteasomal degradation, Ixazomib indirectly inhibits Cdc23 by impeding the proteasomal degradation mechanism. | ||||||